🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Can’t be in person in #SABCS23, but my avatar is there 😏 Here our poster PO3-14-06 dissecting immunologic features and their prognostic relevance in the phase II RCT KENDO trial of HR+HER2neg BC treated with CT or CDK4/6i+ET. Congrats to my great co-first #MichelaPalleschi

#SABCS23 | Poster PO3-16-03 | Investigating #HER2DX genomic assay concordance within HER2-positive #breastcancer. Fara Brasó Maristany Ada Waks Sara Tolaney Otto Metzger Polyak Lab Laia Paré Brunet Guillermo Villacampa @prat_aleix Esther Sanfeliu Ana Vivancos

So grateful for the privilege of being part of this exceptional group!🙌🏼 Tomás Pascual Mafalda Oliveira Eva M Ciruelos Maria Vidal Juanmi Cejalvo Rodrigo Sánchez-Bayona Guillermo Villacampa Meritxell Bellet Cristina Saura Cristina Hernando Milana Bergamino Sirven Juan M. Ferrero-Cafiero Fara Brasó Maristany Montserrat Muñoz Mateu Sonia Pernas

We are very excited of this collaboration with @prat_aleix and Fara Brasó Maristany in the framework of our EU RESCUER project

An honor to be part of this terrific family: #breastcancer team Hospital Clínic Elia Seguí, MD badamo Olga Martínez-Sáez Tomás Pascual Fara Brasó Maristany Laura Angelats Maria Vidal Montserrat Muñoz Mateu @prat_aleix Alberto Indacochea Isabel Garcia Fructuoso #ClinicComprehensiveCancerCenter Bon Nadal 💪🏻

👇Check this new article from our own Benedetta Conte @prat_aleix and Fara Brasó Maristany 👏👏👏

🔬 Excited to share our latest research published in npj Journals , where we explored the effects of cell-cycle inhibition and the immune microenvironment in breast cancer treated with ribociclib and letrozole vs. chemotherapy. A thread 🧵 nature.com/articles/s4152…

#RAGMA24 Fara Brasó Maristany de IDIBAPS actualiza en avances en plataformas y biomarcadores en #cáncerdemama

Fara Brasó Maristany @prat_aleix IDIBAPS Hospital Clínic analyse the genomic factors that affect the response to Patritumab deruxtecan - HER3-targeted therapy - in #BreastCancer patients from the SOLTI-1805 TOT-HER3 trial #CancerResearch Cancer at Nature Portfolio nature.com/articles/s4146…

Happy to share our published review: Hormone receptor-positive early breast cancer in young women: A comprehensive review - Cancer Treatment Reviews cancertreatmentreviews.com/article/S0305-… Tremendous team effort Isabel Garcia Fructuoso Olga Martínez-Sáez Francesco Schettini, MD PhD 🇮🇹🇪🇸🇪🇺 César y j Sanchez Maria Vidal

📢LAST WEEK📢 to register to the Evomet conference "Deconstructing the evolution of metastasis". ⏱️Apply now at evomet-itn.eu/evomet-confere… ➡️Deadline 23rd July

📢Se determina por primera vez un biomarcador que ayuda a seleccionar a las pacientes que más responden a patritumab deruxtecán, uno de los últimos fármacos revolucionarios en cáncer de mama 📖Estudio TOT-HER3: gruposolti.org/ensayosclinico… 🔗Nota de prensa: gruposolti.org/se-determina-p…

Identifican un biomarcador que ayuda a seleccionar a las pacientes que más responden a patritumab deruxtecán, uno de los últimos fármacos revolucionarios en #CáncerMama. 🗞️ Publicado en Nature Communications ➡️ linke.to/TOT-HER3VHIO #TOTHER3

Un biomarcador ajuda a seleccionar les pacients que responen millor al patritumab deruxtecan en #càncerdemama Els investigadors principals de l'estudi, promogut per SOLTI #cancerresearch, han estat @prat_aleix (#CLÍNIC-IDIBAPS) i Mafalda Oliveira (Vall d'Hebron-Vall d’Hebron Institute of Oncology (VHIO)) 👉 i.mtr.cool/xstcruvtcm

📢Development and validation of #TNBCDX a new genomic biomarker for early-stage triple-negative breast cancer with an without pembrolizumab. Published in Annals of Oncology annalsofoncology.org/article/S0923-… @prat_aleix Vall d’Hebron Institute of Oncology (VHIO) Laia Paré Brunet Fara Brasó Maristany REVEAL GENOMICS

🔬ADAPTMET: Un nou horitzó en la investigació de la metàstasi del #càncer. 🚀🇪🇺L'#IRBBarcelona lidera un projecte europeu per formar futurs experts en recerca de la #metàstasi. ➡️tinyurl.com/3vs2wwmc #CancerResearch #Metastasis

Finally out in ESMO Open the main findings of my ESMO - Eur. Oncology #Fellowship research project focused on the identification of predictors of response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in HR+/HER2- #breastcancer. What did we find? A thread 🧵

🛑Now that sacituzumab govitecan (SG) and trastu deruxtecan (TDXd) are available for CT-pretreated HER2-low MBC and ADC sequencing is scarcely effective, which ADC is to prioritise in HR+ and TN BC? We tried to answer with our just-published network meta-analysis! OncoAlert 🧵👇

IDIBAPS @prat_aleix Laura Angelats Fara Brasó Maristany Laia Paré Brunet Carlota Rubio-Perez REVEAL GENOMICS 🆕Identifican un vínculo entre el sistema inmunitario y la supervivencia después de un cáncer de mama 📈Altos niveles de un perfil inmunológico de 14 genes en muestras tumorales se asocian a una reducción significativa del riesgo de mortalidad 👉s.mtrbio.com/tldlyvsijf IDIBAPS

🆕Investigadores del #CLÍNIC-#IDIBAPS han liderat una investigació que ha trobat una relació entre l’activitat immunològica antitumoral i la longevitat en persones supervivents de càncer de mama 👉clinicbarcelona.org/ca/noticies/id…